
## Caroline B Kurtz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1049393/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology, 2018, 36, 857-864.	9.4	373
2	An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Science Translational Medicine, 2019, 11, .	5.8	242
3	DevelopingÂa new class of engineered live bacterial therapeutics to treat human diseases. Nature Communications, 2020, 11, 1738.	5.8	214
4	Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature Metabolism, 2021, 3, 1125-1132.	5.1	72
5	Translational Development of Microbiomeâ€Based Therapeutics: Kinetics of <i>E. coli</i> Nissle and Engineered Strains in Humans and Nonhuman Primates. Clinical and Translational Science, 2018, 11, 200-207.	1.5	24
6	An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and <i>in silico</i> simulations of enteric hyperoxaluria. Molecular Systems Biology, 2022, 18, e10539.	3.2	16
7	Genetically engineered <i>E. coli</i> Nissle attenuates hyperammonemia and prevents memory impairment in bileâ€duct ligated rats. Liver International, 2021, 41, 1020-1032.	1.9	10
8	240 - Genetically Engineered E. Coli Nissle Attenuates Hyperammonemia in a Mouse Model of Hepatic Encephalopathy by Metabolizing Gut Ammonia and Increasing Urea Production. Gastroenterology, 2018, 154, S-1078.	0.6	1